HUM

Humana is a $130B-revenue Medicare-heavy insurer whose growth is intact but whose profitability has collapsed. Revenue has compounded from $83.1B (FY2021) to $130B (FY2025), yet net income fell every year over that span — from $2.93B to $1.19B — and FY2025 net margin is just 0.9% with a 2.1% operating margin and 6.7% ROE. This is the textbook Medicare Advantage margin-compression cycle the 10-K spells out: premiums are 'fixed for one-year periods,' so when medical cost trend and utilization run ahead of pricing assumptions, 'costs we incur in excess of our benefit cost projections generally are not recovered in the contract year.' The benefit ratio is the swing factor, and it has been working against them.

The cash and one-time items deepen the concern. Operating cash flow fell 68.9% to $921M — below reported net income, so cash conversion is under 1x — and management defensively cut buybacks 81.5% to $151M while letting cash build 89% to $4.20B. The MD&A discloses a 'substantial multi-year transformation program' with $449M of value-creation charges in 2025 (on top of $281M in 2024 and $436M in 2023), plus $253M of impairments and the finalized exit from the Employer Group Commercial Medical Products business. These are real signs of a company re-aligning its cost base under 'sustained macroeconomic, regulatory and competitive pressures' — a turnaround in progress, not a stabilized franchise.